Table 2.
Demographic profile and baseline LDL-C values of treatment groups (Study 2).
| SIM 20 mg + EZE 10 mg (n = 8) | SIM 20 mg + EZE placebo (n = 8) | EZE 10 mg + EZE placebo (n = 8) | |
|---|---|---|---|
| Age (years) | |||
| Mean | 38.0 | 37.6 | 33.3 |
| s.e. mean | 2.9 | 2.7 | 2.0 |
| Median | 38 | 36 | 33 |
| Range | 22–49 | 27–47 | 26–43 |
| Baseline weight (kg) | |||
| Mean | 70.3 | 81.0 | 72.3 |
| s.e. mean | 2.9 | 2.0 | 2.9 |
| Median | 72 | 81 | 74 |
| Range | 57–79 | 72–89 | 60–82 |
| Baseline LDL-C (mg dl−1) | |||
| Mean | 183.4 | 157.8 | 168.5 |
| s.e. mean | 11.9 | 6.4 | 9.5 |
| Median | 182 | 159 | 165 |
| Range | 147–221 | 134–181 | 135–197 |
SIM, simvastatin; EZE, ezetimibe; s.e. mean, standard error; LDL-C, low-density lipoprotein cholesterol.